Autonomix Medical (NASDAQ: AMIX), a medical device company focused on precision nerve-targeted treatments, has released its latest CEO Corner segment featuring CEO Brad Hauser. The segment discusses two key updates: the company's recent longer-term post hoc analysis from its first-in-human proof-of-concept study (PoC 1) and progress towards U.S. clinical trials scheduled to begin in 2026.
Autonomix Medical (NASDAQ: AMIX), azienda produttrice di dispositivi medici specializzata in trattamenti mirati al nervo con precisione, ha pubblicato l'ultima puntata della serie CEO Corner con l'amministratore delegato Brad Hauser. Il segmento affronta due aggiornamenti chiave: il recente analisi post hoc a lungo termine del suo primo studio sull'uomo come proof-of-concept (PoC 1) e i progressi verso studi clinici negli Stati Uniti previsti per iniziare nel 2026.
Autonomix Medical (NASDAQ: AMIX), una empresa de dispositivos médicos centrada en tratamientos de precisión dirigidos a nervios, ha lanzado su último segmento de CEO Corner con el CEO Brad Hauser. El segmento aborda dos actualizaciones clave: el análisis post hoc a largo plazo reciente de su primer estudio en humanos como prueba de concepto (PoC 1) y el progreso hacia ensayos clínicos en EE. UU. que se prevé que comiencen en 2026.
Autonomix Medical(NASDAQ: AMIX)는 정밀 신경 표적 치료에 중점을 둔 의료기기 회사로, CEO Brad Hauser와 함께하는 최신 CEO Corner 세그먼트를 공개했습니다. 이 세그먼트는 두 가지 주요 업데이트를 다룹니다: 인간 대상 PoC 1의 장기 후향 분석과 2026년에 시작될 예정인 미국 임상시험으로의 진행.
Autonomix Medical (NASDAQ : AMIX), une entreprise de dispositifs médicaux spécialisée dans les traitements de précision ciblant les nerfs, a publié son dernier segment CEO Corner avec le PDG Brad Hauser. Le segment aborde deux mises à jour clés : la récente analyse post hoc à long terme de sa première étude chez l’homme de preuve de concept (PoC 1) et les progrès vers des essais cliniques américains prévus pour commencer en 2026.
Autonomix Medical (NASDAQ: AMIX), ein Hersteller von medizinischen Geräten mit Fokus auf präzise nervenzielgerichtete Behandlungen, hat sein aktuelles CEO Corner-Segment mit dem CEO Brad Hauser veröffentlicht. Das Segment behandelt zwei wichtige Aktualisierungen: die jüngste Post-hoc-Analyse mit langfristiger Laufzeit aus seiner ersten Human-Proof-of-Concept-Studie (PoC 1) und Fortschritte in Richtung US-klinischer Studien, die 2026 beginnen sollen.
Autonomix Medical (القائمة في ناسداك: AMIX)، شركة أجهزة طبية تركز على العلاجات الدقيقة المستهدفة للأعصاب، أصدرت أحدث فقرة من سلسلة CEO Corner مع المدير التنفيذي براد هاوزر. تناقش الفقرة تحديثين رئيسيين: تحليل ما بعد الحدث على المدى الطويل الأحدث من دراستها الأولى على البشر كدليل مفهوم (PoC 1)، والتقدم نحو التجارب السريرية الأمريكية المزمع بدؤها في 2026.
THE WOODLANDS, TX, Oct. 02, 2025 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company dedicated to advancing precision nerve-targeted treatments, today announced the next CEO Corner segment has been published on the Company’s website. For the CEO Corner segment, Brad Hauser, CEO of Autonomix, discusses the Company’s recently announced longer-term post hoc analysis from its first-in-human proof-of-concept study (“PoC 1”) and recent progress made towards the start of U.S. clinical trials, on track to begin in 2026.
Autonomix is a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated. The Company’s first-in-class platform system technology includes a catheter-based microchip sensing array that may have the ability to detect and differentiate neural signals with greater sensitivity than currently available technologies. We believe this will enable, for the first time ever, transvascular diagnosis and treatment of diseases involving the peripheral nervous system virtually anywhere in the body.
We are initially developing this technology for the treatment of pain, with initial trials focused on pancreatic cancer, a condition that causes debilitating pain and is without a reliable solution. Our technology constitutes a platform to address dozens of potential indications, including cardiology, hypertension and chronic pain management, across a wide disease spectrum. Our technology is investigational and has not yet been cleared for marketing in the United States.
When will Autonomix Medical (AMIX) begin its U.S. clinical trials?
According to the announcement, Autonomix Medical is on track to begin U.S. clinical trials in 2026.
What did Autonomix Medical's CEO discuss in the latest CEO Corner segment?
CEO Brad Hauser discussed the company's longer-term post hoc analysis from its first-in-human proof-of-concept study and progress towards upcoming U.S. clinical trials.
Where can investors find Autonomix Medical's latest CEO Corner segment?
The CEO Corner segment is available on Autonomix Medical's company website.
What is Autonomix Medical's (AMIX) main business focus?
Autonomix Medical is a medical device company dedicated to advancing precision nerve-targeted treatments.
An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, to receive support.
